Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hCMV Receptor Decoy
- Development stage
- Preclinical
- Lead developer
- Cyrus Biotechnology
- Modality
- Recombinant Proteins and Enzymes
01
Overview
The hCMV Receptor Decoy is an engineered protein therapeutic being developed by Cyrus Biotechnology in collaboration with the University of Illinois. Designed using proprietary computational protein engineering and AI platforms, the drug acts as a soluble receptor decoy composed of engineered variants of the Platelet-derived growth factor receptor alpha (PDGFRα). PDGFRα is the natural host cell receptor used by Human Cytomegalovirus (hCMV) to enter fibroblasts and other cell types via the viral gH/gL/gO trimeric complex. By mimicking this receptor with high affinity, the therapeutic binds to the virus and blocks its ability to interact with actual cell-surface receptors, thereby neutralizing the infection. The primary clinical focus is the prevention and treatment of congenital hCMV infections, which are a leading cause of birth defects and permanent hearing loss in infants.
- Other names
- PDGFRα-based hCMV decoyengineered PDGFRα decoyhCMV receptor decoy-Cyrus Biotechnology
02
Targets
Human cytomegalovirus glycoprotein H/glycoprotein L/glycoprotein O complexPDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on hCMV Receptor Decoy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hCMV Receptor Decoy.